Seeing Through the Haze: The Radiologist’s Challenge in Diffuse Liver Disease

Diffuse liver disease is an umbrella term referring to various conditions, including diffuse steatosis of different origins, iron overload, fibrosis, and cirrhosis. In the field of imaging specifically, researchers have primarily focused on characterizing and estimating the severity of diffuse liver disease, while the impact of diffuse liver disease on the detection and characterization of focal liver lesions that develop in its presence has received less attention.

In recent years, metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty liver disease, has become the leading cause of chronic liver disease worldwide. ¹ In parallel, diffuse liver disease has become a silent but formidable confounder in abdominal imaging. As metabolic syndrome, viral hepatitis, and alcohol-related injury reshape the hepatic parenchyma, radiologists are increasingly faced with the diagnostic challenge of multiple imaging pitfalls encountered in diffuse liver disease. These pitfalls include pseudolesions and altered parenchymal enhancement, which make a specific diagnosis difficult, as well as masked lesions.

In this issue of the Canadian Association of Radiologists Journal, Shyamanur et al offer a relevant and timely synthesis of how steatosis, fibrosis, and cirrhosis generate pseudolesions, alter lesion conspicuity, mask lesions, and modify enhancement patterns across modalities. ² Ultimately, these factors reduce diagnostic confidence. ² Shyamanur et al propose a multimodality strategy centered on magnetic resonance imaging (MRI), including subtraction imaging, ³ and contrast-enhanced ultrasound (CEUS). Their emphasis on integrating quantitative MRI tools, such as chemical-shift imaging, diffusion-weighted imaging, and hepatobiliary-phase contrast, aligns with current trends in precision imaging.

For the practicing radiologist, the review of Shyamanur et al highlights several actionable principles. ² First, it is important to distinguish pseudolesions, such as focal fat sparing, from tumors because they lack mass effect, exhibit a characteristic enhancement delay and have suggestive and characteristic locations, and shapes. ⁴ Second, one must be aware of the “vanishing washout” of hepatocellular carcinoma. The attenuation gap between hepatocellular carcinoma and steatotic liver parenchyma narrows, which can lead to a falsely negative interpretation of a computed tomography (CT) examination. MRI subtraction imaging and CEUS can restore diagnostic specificity. Third, a “negative” CT examination should not be trusted in patients with marked steatosis because sensitivity for small lesion detection significantly drops in steatotic liver. ² Diffuse liver disease decreases the contrast between lesions and the liver, so MRI with diffusion-weighted imaging or hepatobiliary agents is essential for staging malignancy or detecting metastases.

Shyamanur et al expand the scope of their article from lesion detection to pathophysiologic imaging. ² Quantitative biomarkers such as proton density fat fraction, elastography, and R2* relaxometry are redefining how we stage diffuse liver disease and interpret focal findings within it. ⁵ For instance, combining MRI-proton density fat fraction and MR elastography maps both steatosis and stiffness, providing a dual assessment of metabolic and fibrotic burden. This synthesis supports personalized imaging follow-up and risk stratification.

For radiologists, this review transforms familiar challenges into a structured diagnostic algorithm. The relevance of this algorithm is magnified by the increasing prevalence of MASLD, which now affects up to a quarter of the global population. Thus, radiologists are not merely interpreters, but also gatekeepers of the early detection of hepatic neoplasia within this vast cohort. The clinical message is clear. Radiologists need to tailor imaging protocols to the parenchymal background and use MRI when CT fails. They should also incorporate CEUS for dynamic lesion evaluation when radiation or renal function limit alternatives. They should apply LI-RADS criteria cautiously, acknowledging that steatosis can obscure washout or alter enhancement kinetics. ² However, this phenomenon is probably not so common as suggested by Park et al ⁶ and Barat et al. ⁷

In conclusion, Shyamanur et al offer a much-needed roadmap for navigating the deceptive imaging landscape of diffuse liver disease. ² By combining physiological understanding with advanced imaging technique, they enable radiologists to regain the diagnostic confidence eroded by steatosis and fibrosis. Their work reaffirms MRI and CEUS as linchpins of hepatic precision imaging. The implications of their work are significant because misclassifying lesions in steatotic or fibrotic livers can delay oncologic management and affect transplantation eligibility or result in unnecessary biopsies. Future research should build upon comparative performance analyses that quantify how new quantitative biomarkers improve lesion detection thresholds across diffuse liver disease phenotypes. Artificial intelligence tools trained on multi-parametric MRI could further standardize these complex interpretations.